LENSAR Inc (LNSR) Stock AnalysisLNSRLENSAR Inc

LENSAR, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. The Company's product portfolio includes the LENSAR Laser System and the ALLY Robotic Cataract Laser System and their associated consumable components. It has developed its ALLY System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating artificial intelligence into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing its advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite. ALLY allows the surgeon to switch between cataract laser and the surgeon’s existing phacoemulsification device without moving patients from room-to-room. ALLY includes its proprietary Streamline software technology. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

LENSAR Inc is a good buy right now due to its current price of $8.30, which is below the analyst price target of $10 to $13, suggesting a significant upside potential. Additionally, the company has shown a gross margin improvement to 57.88% in Q2 2026, indicating better profitability. However, a risk to consider is the 5-day change of -4.38%, reflecting recent volatility in the stock price.